LUXEMBOURG BIOHEALTH CAPABILITIES - IBBL · The Luxembourg BioHealth Cluster was established in...

TURNING INNOVATION INTO BUSINESSNOVEMBER 2013

LUXEMBOURG BIOHEALTH CAPABILITIES

3

EDITORIALby Jean-Paul Scheuren, President, Luxembourg BioHealth Cluster

Luxembourg is home to a young, dynamic biomedical sector, which specialises in fields such as personalised medicine, medical devices, diagnostics, bioinformatics and telemedicine. The sector is of strategic importance for Luxembourg’s economy, and its development is backed by solid governmental support.

The Luxembourg BioHealth Cluster was established in 2008 in order to bring together the actors in the biomedical field and to enhance the Grand Duchy’s reputation as a recognised and attractive environment for biomedical research, innovation and business. It is experiencing strong growth and currently includes private companies, public research organisations and specialised service providers as well as strategic partners such as the Ministry of the Economy and Foreign Trade, the Ministry of Higher Education and Research, the Ministry of Health and the National Research Fund.

Health sciences and technologies is a highly competitive field, and collaboration between different actors with complementary competences is essential for business and research development. This catalogue showcases the skills, activities and offers of our members, and is a useful guide to anyone interested in establishing R&D collaborations and business relationships in the biomedical field.

I thus invite you to discover the capabilities of our members and welcome potential partners to contact the Cluster’s management team. A key role of the BioHealth Cluster is to assist players interested in establishing relationships with the biomedical sector in Luxembourg, or even in locating activities here. We would be delighted to provide you with support, information and further contacts.

LUXEMBOURG BIOHEALTH CAPABILITIES

Follow us on Twitter (@Luxbiohealth) and LinkedIn

CONTACTDr Thomas DentzerLuxembourg BioHealth Cluster [email protected] Phone: +352 43 62 63 875

Dr Françoise MeischCluster [email protected] Phone: +352 43 62 63 655

More informations on the Luxembourg Biohealth Cluster:www.biohealthcluster.lu

2 LUXEMBOURG BIOHEALTH CAPABILITIES


Community management • Information exchange platforms • Tailored information/opportunities • Networking (Events, visits,…)

Sector development • Attraction of companies • Contribute to a competitive and favourable environment • Foster synergies

Global trends • Market studies • Market/business intelligence • Trend & technology scouting

Internationalisation • Access to international events • Support to international co-operations • International partnerships

Co-operations • Initiation & support of co-operation projects • Partner matchmaking • Project management

Marketing & PR • Information and marketing material • Generation of a national identify • Trade fairs, company visits

5LUXEMBOURG BIOHEALTH CAPABILITIES

LUXEMBOURG BIOHEALTH CLUSTERThe Luxembourg BioHealth Cluster aims to strengthen and capitalise on the national strategy developed by Luxembourg’s government to achieve scientific excellence in molecular diagnostics, the cornerstone of personalised medicine. Its members are R&D companies, public research organisations, laboratories, hospitals and other actors (patients associations, service and capital providers, etc) whose activities are related to health sciences and technologies.

With a principal focus on molecular diagnostics, the Cluster’s umbrella also covers other research and business fields that are key elements in an integrated patient-based personalised medicine approach, such as new therapeutics, bioinformatics, medical device and telemedicine. Supporting this dynamic and steadily growing biocommunity is the main objective. Therefore, the Cluster provides its members with a portfolio of added-value activities and services to support them in their daily R&D, innovation and business challenges and to increase their national and international visibility and attractiveness.

THE LUXEMBOURG BIOHEALTH CLUSTER OFFERS THE FOLLOWING SERVICES:

Cluster management teamThe Luxembourg BioHealth Cluster activities and support services are managed by Luxinnovation, the National Agency for Innovation and Research. A dedicated Cluster management team is in charge of the daily operational tasks dealing with the implementation of the Cluster strategy and the Cluster Action Plan.

Are you interested in Luxembourg?The Cluster provides foreign companies interested in locating activities in the Grand Duchy with information about the Luxembourg biomedical sector. We can advise you on available support measures, assist you in identifying suitable premises and put you in touch with relevant collaboration partners to set up your activities in Luxembourg.

More informations on Luxembourg Biohealth Cluster:www.biohealthcluster.lu

SUMMARY

ACTIMAGE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 08

Advanced Biological Laboratories (ABL) / TherapyEdge INC . . . . . . . . . 10

APL – Association pharmaceutique luxembourgeoise . . . . . . . . . . . . . . . 12

AxoGlia Therapeutics S.A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14

Cellon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

Complix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18

Fast Track Diagnostics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20

Flen Pharma S.A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22

House of Biohealth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24

Laboratoires Réunis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26

LuxFold S.A. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28

Neo Medical Systems . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30

Simeda . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32

T&E Gefahrgutlogistik AG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34

WaferGen Biosystems Europe S.à r.l. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36

CRP Henri Tudor: Resource Centre for Health Care Technologies (CR SANTEC) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38

IBBL (Integrated BioBank of Luxembourg) . . . . . . . . . . . . . . . . . . . . . . . . . . 40

Luxembourg Centre for Systems Biomedicine (LCSB) . . . . . . . . . . . . . . . 42

University of Luxembourg: Life Sciences Research Unit . . . . . . . . . . . . . 44


7LUXEMBOURG BIOHEALTH CAPABILITIES

PUBL I C RESEARCH

PR IVATE SECTOR

98 LUXEMBOURG BIOHEALTH CAPABILITIES LUXEMBOURG BIOHEALTH CAPABILITIES

CEO Christophe Megel

CREATION DATE 1995

EMPLOYEES 100-249

TURNOVER 2012 €10,000,000

TRADING AREA Europe

R&D INTERNAL INVESTMENTS 2012 15% of turnover

CERTIFICATIONS, QUALIFICATIONS, Microsoft Gold Partner

INTERNATIONAL LOCATIONS Europe

ADDRESS224 rue de Beggen L-1220 Luxembourg

CONTACTSandrine Boussonnie Tel: +352 27 62 15 15 [email protected]

WEBSITEwww.actimage.com

CORE BUSINESSACTIMAGE focuses on six main areas:

• Application Development in .Net, Java, PHP

• Development of mobile applications on Smartphones (iPhone / iPad, BlackBerry, Android, Windows 7, SmartTV)

• Ergonomics and design

• E-infrastructure

• Assistance with project management

• Participation in European projects for collaborative research

PRODUCTS & SERVICESActiBOX - “More than a CMS”: Management tool, web content 2.0 OpenSource Technologies Ergonomic administration interface

Actinote - “Another way of writing”: Scans your handwritten information, sends them from anywhere directly into your information system

ActiNet - “For a good organisation”: A collaborative system of management and internal monitoring

Software development

Web & mobile development

Cloud computing and SAAS

Consulting & audit

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSActimage has 6 years of experience in R&D projects. Currently, Actimage is involved in 3 Ambient Assisted Living (AAL) projects (Care@Home, M3W and SALIG ++). In these projects Actimage is in charge of the device platform development, the definition of the architecture of the solution, interface software development, mobile development, smartTV development, serious games platform development and data hosting.

ACTIMAGE also developed Actelin. It is a smartphone application for diabetic patients under insulin. This application is available on android and iOS.

TECHNICAL / TECHNOLOGICAL CAPABILITIESACTIMAGE staff includes project managers, engineers, developers, security engineers and IT consultants.

ACTIMAGE has expertise in:

• Software development ( Java, J2EE, C#, .NET, Perl, Python, Ruby)

• Web, mobile and smartTV development (PHP, HTML 5, iOS, Android, Windows Mobile, Balckberry, objective C, Jahia, Sharepoint, Drupal, …)

• Cloud computing

• Databases (SQL, Oracle)

TECHNICAL MEANS / EQUIPMENTACTIMAGE has a hosting platform and all types of devices (Smartphone, tablets and smartTV). We are able to develop for all types of platforms (android, iOS, blackberry, Windows Mobile).

MAIN CUSTOMERS/COLLABORATIONSInstitutions: European institutions, French Department of Economics and Finance, French Department of Ecology, Ministry of Social Affairs, Luxembourg Ministry of the Economy and Foreign Trade, Luxembourg Ministry of Foreign Affairs, ENA, DGME, National Institute of Appellations of Origin (INAO), INSEE, SIGI

Banking institutions: Credit Agricole, BCEE and BCL

Media - Telecom - Industry: ALCATEL BUSINESS SYSTEM, EDITUS, Schlumberger, Siemens, TANGO

Health - Medicinal - Social: WEBSURG, NETWORK CAROL, SCHILLER MEDICAL

ACTIMAGE

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Dr Chalom B. SAYADA, MD, PhD

CREATION DATE 2000

EMPLOYEES 10-49

TRADING AREA International

CERTIFICATIONS, QUALIFICATIONS, CE marking for TherapyEdge and In-Vitro Diagnostic use for ViroS-core and DeepChek. Final-Five participant of the 2013 Innova-tion Prize (Universal Biotech) for DeepChek.

INTERNATIONAL LOCATIONS Greater Region, Europe, Africa, Oceania

ADDRESS2, rue des Dahlias L-1411 Luxembourg

CONTACTDr Chalom SayadaTel: +352 26 38 89 [email protected]

WEBSITEwww.ablsa.com

CORE BUSINESSAdvanced Biological Laboratories (ABL) works in the field of Healthcare Information Technology (HIT). It is a spin-off from CRP-Santé’s Retrovirology laboratory.

ABL develops clinically validated HIT systems that empower clinicians to improve treatment decisions. With an initial strategic focus on diagnostics for HIV and viral hepatitis (HBV and HCV), ABL continues its efforts towards healthcare professionals with critical, actionable information. The aim is to improve patient care and management through the commercialisation and development of advanced genomic analysis technologies in infectious diseases, bacteriology and oncology.

DeepChek® software is the first and only commercially available CE-mark downstream analysis software for In-Vitro Diagnostic use in the field of Next Generation Sequening (NGS). In order to complement its own software licensing revenues, ABL acquired TherapyEdge Inc in 2004 and Evivar Medical in 2013.

ABL has licensed in several algorithms, knowledge database, patents and services from international universities and key opinion leaders. It has a portfolio of more than 25 issued international patents.

PRODUCTS & SERVICESABL develops and implements several products and services around its web-based and local TherapyEdge Box System to deliver the best therapies for people living with complex, chronic diseases:

• TherapyEdge-HIV is an HIV specific patient record, decision support, monitoring and reporting system with built in HIV specific decision support (TherapyEval) and various modules (RapidCapture, Down-Referral, Peads, HealthScan, Chronic, eRegister);

• ViroScore Suite is an HIV drug resistance interpretation system and sequence storage database with built-in analysis and reporting tools;

• SeqHepB is an online decision support system for HBV drug resistance information acquired from Evivar Medical (co-developed with Melbourne Health University, Australia) with the largest HBV drug resistance knowledge database;

• DeepChek®-HIV is the first CE-IVD marked medical device for Next Generation Sequencing data management (Roche 454, Illumina MiSeq/HiSeq, Ion Torrent PGM, SmartR PacBio, ...). DeepChek modules for HBV and HCV are also available for NGS;

• ABL is currently developing DeepChek modules for other applications around full genome for specific viruses, oncology and bacteriology;

• ABL is also involved in various projects focusing on generic NGS data management (TBS);

• VisibleChek is the first-application for data visualization and data mining able to merge clinical, virological and advanced molecular (Sanger/NGS) information;

• HepatiC is a viral hepatitis C patient registry and database to monitor and screen HCV infected patients.

Advanced Biological Laboratories TherapyEdge INC

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSSince 2000, ABL has leveraged a large experience in HIV and viral hepatitis patient management and drug resistance interpretation. ABL has acquired the assets of TherapyEdge Inc for HIV and Evivar Medical Pty for HBV. These assets are patents, software and knowledge databases. ABL continue investing resources in infectious diseases to support its product portfolio.

ABL is also engaging strong collaborations in the fields of bacteriology and human genetics for developing new applications in tuberculosis and oncology.

ABL continues its efforts to bring the latest technologies for server virtualisation, web development with strong capacities of data security and data encryption, bioinformatics scripts and methods for fast and reliable data management and analysis of Next Generation Sequencing information.

TECHNICAL / TECHNOLOGICAL CAPABILITIESABL is able to develop secure network (Intranet, Internet, VPN) platforms for the electronic management of clinical information between distributed units. ABL’s technology is a ready-to-run solution for all the technical problems that users face. The developed platforms are based on state-of-the-art technologies. ABL offers a service adapted to each clinical setting and can implement electronic case report forms. The company can combine the secure collection of data with real time analysis systems.

ABL is also able to develop specifically:

• algorithm-based genotype interpretation systems;

• tools for the management of sequences;

• advanced genetic analysis tools to integrate complex clinical and virological information.

TECHNICAL MEANS / EQUIPMENTABL products lie on a proprietary platform server (hardware, virtual or internet-based). End-users access the various pieces of software using web-browser. It could be used by clinicians, pathology laboratories, private insurance companies, diagnostics and pharmaceutical companies.

ABL’s platform is fully integrated with patient management systems (PMS or HER), pharmacy information system (PIS), laboratory information system (LIS) using its integration engine with standard data exchange protocols (HL7, XML). It could be integrated to any type of network to implement new electronic case report forms, engage specific data collection on investigating sites, generate printout of case report forms in paper format (PDF), display graphics for patients, automated data extraction, database query, push technologies (alerts, SMS ...).

MAIN CUSTOMERS/COLLABORATIONSCentre de Recherche Publique - Santé, Luxembourg, Luxembourg

Federal University of Sao Paulo, Sao Paulo, Brazil

AEEH, Spanish Association of Hepatologists for HCV

Spanish HIV Fundation (Badalona, Barcelona) for HIV & NGS

WITS University – Medical School

European Society for Antiviral Resistance

TINN2 (FP7 EU Project)

Roche Diagnostics International

Other Pharma and Dx companies (HIV, HCV, HBV, oncology)

PR IVATE SECTOR

PUBL IC RESEARCH


Secretary General Hendrik Kühne

CREATION DATE 2011

EMPLOYEES 0-9

TURNOVER 2012 €170,000

TRADING AREA Luxembourg


ADDRESS7, rue Alcide de Gasperi L – 2981 Luxembourg

CONTACT Hendrik KühneTel: +352 26 43 23 [email protected]

WEBSITEwww.apl-pharma.lu

CORE BUSINESSThe Association pharmaceutique luxembourgeoise (APL) is the representative body for the innovative pharmaceutical industry active in Luxembourg. With 36 members (as of October 2013), the APL covers some 72% of the pharmaceutical market in Luxembourg. The APL being a young association, the number of members is still growing.

The main goal of the APL is to establish an open and trustworthy contact with Luxembourg decision-makers and stakeholders in order to promote stability, predictability and a general dialogue in partnership.

PRODUCTS & SERVICESAPL wants to promote stability for the Luxembourg pharmaceutical market. This means access for everyone to all available treatments, and this over a longer period of time. The current Luxembourg health system is characterised by high investments in general and good quality for patients regarding the access to new medications. In order to maintain these special Luxembourg qualities, APL would like to engage with national authorities in official discussions on future challenges for the health care system. This would in particular be to contribute to realistic budgetary previsions.

On the other hand and towards its members, APL is promoting Luxembourg as a possible partner in R&D activities, in particular putting forward CRP-Santé, IBBL, LCSB, and other prominent bodies in the research field in Luxembourg.

APL would like to see all concerned authorities engaging together in a broad dialogue about the future of possible pharmaceutical investments in Luxembourg, in order to benefit patients (quick access to innovation), the Luxembourg economy (employment and tax revenues), research as a whole in Luxembourg (abovementioned bodies as well as researching practitioners), and industry (stability and predictability).

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSAchieving a mid- and long-term previsibility of national health economics.

TECHNICAL / TECHNOLOGICAL CAPABILITIESPharmaceuticals

MAIN CUSTOMERS/COLLABORATIONSPublic health care authorities and other stakeholders in public health.

APLAssociation pharmaceutique luxembourgeoise

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Jean-Paul Scheuren

CREATION DATE 2006

EMPLOYEES 0-9

TRADING AREA Europe

R&D INTERNAL INVESTMENTS 2012 €200,000

ADDRESS162a avenue de la Faiencerie L-1511 Luxembourg

CONTACT Dr Djalil Coowar Tel: +352 46 66 44 64 45 [email protected]

WEBSITEwww.axoglia.com

CORE BUSINESSAxoGlia Therapeutics is a biopharmaceutical company focused on the discovery and development of innovative drugs for the treatment of neurodegenerative and inflammatory diseases with unsatisfied medical needs (Multiple Sclerosis, Parkinson’s Disease...).

The company is a pioneer in the development of small chemical entities having dual anti-neurodegenerative and anti-inflammatory capacities. These molecules act on two levels: the regeneration of nervous cells by influencing the cell fate of cellular precursors and having anti-inflammatory/neuroprotective properties.

PRODUCTS & SERVICESAxoGlia pipeline consists of drug candidates aiming to stimulate and promote the patient’s own resident neural stem/progenitor cells to differentiate and become functional for endogenous repair. AxoGlia responds to an unmet medical need as no medication currently marketed or close to marketing approval has demonstrated a curative effect for either pathology. Our lead compounds for MS have anti-inflammatory activities and the capacity to promote the differentiation of oligodendrocyte precursor cells for enhancing remyelination processes and axonal protection.

Company highlights:

• Cell-based functional analysis to identify the right lead compounds

• Focus on brain repair by CNS regeneration and neuroprotection for a curative approach

• Assays combine neurogenesis enhancement, neural precursor cell differentiation and neuroprotection

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSWe have identified Glycogen Synthase Kinase-3 (GSK-3) inhibitors which are able to modulate the activation of microglia and polarise them towards a neuroprotective profile with the secretion of anti-inflammatory and anti-oxidant molecules. These inhibitors have demonstrated these anti-inflammatory characteristics through the activation of the Nrf2 pathway. These findings pave the way for rapidly developing a preclinical drug candidate for MS or PD. This opens a real perspective for the development of AxoGlia’s pipeline of drug candidates.

A major project financed by the Michael J Fox Foundation is to determine if disrupting the inflammatory CD40-CD40L pathway is of therapeutic benefit in mouse models of PD. This could open a new avenue for therapeutic intervention in PD. Antibodies neutralising CD40 or CD40L exist and are currently being clinically tested to treat autoimmune diseases and organ rejection after transplantation. They could be tested in PD models in a follow-up to our study.

TECHNICAL / TECHNOLOGICAL CAPABILITIESOur drug discovery platform consists of functional screens for assessing cell differentiation and immunomodulatory capacities. At first, compounds are evaluated on Neural Stem Cells (NSCs) and macrophages for these activities and further in vitro tests on primary cells are realised to confirm the CNS regenerative and anti-inflammatory potential of hit candidates.

Depending on early PK studies of hit candidates, pharmacological validation on animal models is then realized to assess the clinical outcome for MS and PD. Our mission is to identify the most promising candidates for a regenerative approach to CNS diseases.

MAIN CUSTOMERS/COLLABORATIONSAxoGlia works with scientific and clinical key opinion leaders in neurodegenerative disorders. Collaboration is ongoing with the Luxembourg Centre for Systems Biomedicine for systems biology approaches to understand the molecular mechanisms leading to PD and to identify new innovative therapeutic targets. A scientific partnership has also been developed with a Spanish academic group to develop new innovative drug candidates focusing on neurogenesis and neuroprotection.

AxoGlia Therapeutics S.A.

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Richard Fry

CREATION DATE 1987

EMPLOYEES 10-49


CERTIFICATIONS, QUALIFICATIONS, ISO 9001 - 2008


ADDRESSZAE Robert Steichen 16 Rue Hèierchen L-4940 Bascharage

CONTACT Richard Fry Tel: +352 26 33 73 1 [email protected]

WEBSITEwww.cellon.lu

CORE BUSINESSCellon provides products and services to the vaccine production and bioprocessing industries, including the manufacture of:

• PharmaTainers - sterile, single use bottles and carboys for the storage and transport of bulk vaccines , biopharmaceuticals, culture media and other biotech materials that are certified to USP 788, EP 2.9.19 and JP 14th ed. Part 1 sect 24 criteria for particulate in injectable liquids.

• Octopus Assemblies – Custom assemblies developed to meet specific customer requirements for closed liquid transfer solutions.

PRODUCTS & SERVICESCellon’s areas of expertise include mammalian cell culture processes, 3D tissue culture, tissue engineering, storage and transport of sterile liquids and vacuum measurement.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSCellon undertakes a wide range of collaborative development projects with customers to develop custom solutions to their specific requirements forasceptic liquid transfer.

In addition Cellon is coordinating the EU FP7 project SpeCCC.

The core objective of the SpeCCC project is to develop specialised 3D functional liver Cell carrier components for use in homogeneous scalable bioreactor systems, including specialised liver cell lines, specialised cell carriers, a bioartificial liver device (BAL), a multibioreactor platform format for drug testing and biotransformations and a multiwall plate system incorporating specialised carrier components for drug testing and toxicity testing.

TECHNICAL / TECHNOLOGICAL CAPABILITIESClean manufacture (particle free) of single use disposables.

The Rotary Cell Culture System from Synthecon is a unique bioreactor system. The RCCS creates an environment that enables extremely fragile cell cultures and co-cultures of human and animal cells to grow into complex, sophisticated three-dimensional models in vitro. The cultures mimic the structure and function of their parental tissue.

The RollerCell 40 is a roller bottle processing system. It has been designed to automate all stages of roller bottle based cell culture - from cell inoculation, incubation, media change and tryptinisation through to final harvest.

The EggMaster III egg cutting and harvesting system provides fast and effective inspection and processing of inoculated, embryonated eggs for the biotechnology industry.

The VacTester XK systems have been developed to provide rapid, reliable and non destructive detection and quantification of vacuum within vials of parenteral drugs.

Octopus Assemblies are custom designed assemblies for biopharma manufacturers.

TECHNICAL MEANS / EQUIPMENTPharmaTainers are manufactured in a state of the art ISO class 5 (class 100) environment and batch release tested by liquid particle count technology to enable certification to meet USP 788 EP 2.9.19 and JP 14th ed. Part 1 sect 24 criteria for particulate in injectable liquids.

Octopus Assemblies is custom-designed for biofunctional manufacturers. Octopus Assemblies are manufactured at an ISO 9001/2000, BS EN ISO 13485:2003, FDA registered facility in a BS ISO 14644-1:1999 ISO Class 7 (Class 10,000) Cleanroom.

MAIN CUSTOMERS/COLLABORATIONSCellon is an established supplier to many of the largest biopharma, human and animal vaccine manufactures in Europe and worldwide.

Cellon

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Dr Mark Vaeck

CREATION DATE 2008 (Belgium) 2010 (Luxem-bourg)

EMPLOYEES 10-49

TRADING AREA Europe


ADDRESS84 Val Fleuri L-1526 Luxembourg

CONTACT Sabrina Deroo Tel: +352 26 97 02 13 [email protected]

WEBSITEwww.complix.com

CORE BUSINESSComplix is a biopharmaceutical company focused on the discovery and the development of Alphabodies™, a unique class of therapeutics with the capacity to address a vast number of disease targets that are currently considered “undruggable” by the two main classes of therapeutics: small chemical drugs and therapeutic antibodies.

Alphabodies™ bind with high affinity to a wide range of disease targets and are particularly suited to address certain targets that are difficult to reach with antibodies or other types of protein scaffolds. In particular, the ability of Alphabodies™ to modulate the intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of many important diseases, represents a major medical and commercial opportunity for Complix and its partners. Due to their unique stability and versatility Alphabodies™ can be delivered via alternative non-injectable routes of administration, unlike most therapeutic proteins.

PRODUCTS & SERVICESThe Alphabody™ drug development engine is based on the vision that an ideal therapeutic protein should contain a set of key properties that are not present, in a combined way, in monoclonal antibodies or in any other currently available therapeutic proteins. By integrating structural properties of certain naturally occurring human proteins with computer-aided design concepts, the scientific founders of Complix have developed a novel protein scaffold that harbors many of the desired characteristics of an optimal therapeutic molecule: the “Alphabody™”.

Alphabodies™ are a revolutionary class of protein therapeutics that combine the attractive features of antibodies, including high target specificity and affinity, with the benefits from small chemical drugs, such as extreme stability and their capacity to penetrate cells. These unique features enable Alphabodies™ to address a wide range of disease targets, both intracellular and extracellular, that are considered undruggable by current drug formats, namely small chemicals or biologics.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSComplix has been developing Cell-Penetrating Alphabodies (CPABs), which have the unique capacity to enter cells effectively and modulate intracellular protein-to-protein interactions (PPIs), which are known to play a key role in the initiation and progression of major diseases such as cancer, autoimmunity, CNS and metabolic diseases.

TECHNICAL / TECHNOLOGICAL CAPABILITIESBy integrating expert knowledge on structural elements of naturally occurring human proteins with computer-aided rational design concepts, the scientific founders of Complix have created a novel protein scaffold that harbors many of the desired characteristics of an optimal therapeutic molecule: the “Alphabody™”. Applying their proprietary AlphaSelect technology, Complix researchers have already isolated and characterised Alphabodies™ that bind selectively to functional targets involved in the inflammation cascade, in tumor growth regulation and in viral infection.

Through the filing of several broad patent applications Complix has established a strong intellectual property position on the Alphabody™ technology. Because the Alphabody™ scaffold structure is totally unrelated to immunoglobulins, Alphabodies™ are independent of antibody based patent claims.

MAIN CUSTOMERS/COLLABORATIONSComplix has established research alliances with VIB, a Life Sciences Research Institute in Belgium and the Centre de Recherche Public Sante, a public research organisation for basic, pre-clinical and clinical research in life sciences in Luxembourg.

Complix

Structure of an Alphabody

Intracellular presence of cell penetrating Alphabody

PR IVATE SECTOR

PUBL IC RESEARCH


INTERNATIONAL NETWORK MANAGER Graham Samson

CREATION DATE 2006

EMPLOYEES 10-49

TURNOVER 2012 >€6,000,000



CERTIFICATIONS, QUALIFICATIONS, Almost all of our assays are CE labelled and have fulfilled the strict criteria of ISO 13485:2003 since August 2011.

INTERNATIONAL LOCATIONS Europe, Asia

ADDRESS38, rue Hiehl, Z.A.C Laangwiss L-6131 Junglinster

CONTACT Graham Samson Tel: +352 78 02 90 329 [email protected]

WEBSITEwww.fast-trackdiagnostics.com

CORE BUSINESSFast-track Diagnostics specialises in the design, development and manufacture of infectious disease detection kits that use Real Time PCR. Our assays are validated on clinical samples and detect a comprehensive range of viruses, bacteria, fungi and parasites; they are in routine daily use in over 200 laboratories worldwide.

PRODUCTS & SERVICESOur tests are grouped to aid the identification of the underlying cause of most infection syndromes facing the clinician - for example; respiratory, diarrhoea, meningitis, red eye and fever - this means that the clinician does not need to request that a specific pathogen be tested for in a patient sample, which is usually very difficult using clinical criteria alone.

As all our assays are multiplexed, this not only allows the detection of all the pathogens causing a patient’s illness, but it is also the most cost-effective way of detecting multiple pathogens in one tube. By eliminating the need for additional tubes, more reagents and most importantly, more polymerase enzyme - the most expensive ingredient of the reaction - we keep the cost per patient sample to a minimum.

We offer kits packaged to suit small, medium-sized and large laboratories. The 4 patient-per-run size comes in 24 patient tests per kit; the 6 patient-per-run size comes in 48 patient tests per kit; and the 12 patient-per-run size comes in 96 tests per kit.

The laboratory work-flow is simplified and more time-efficient as all our assays are performed using identical extraction and pipetting protocols, and use the same thermal cycling profile to allow faster through-put and more effective use of Real Time PCR platforms.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSWe have a commitment to research and diagnostic laboratories in the emerging world and our kits are used by the GABRIEL network, for projects funded by the Wellcome Trust and the Bill and Melinda Gates Foundation-funded PERCH project.

TECHNICAL / TECHNOLOGICAL CAPABILITIESWe offer more than 40 different Real Time PCR assays detecting more than 100 different pathogens. Our aim is to offer affordable, high quality products for all sizes of diagnostic and research laboratories.

TECHNICAL MEANS / EQUIPMENTAs the Fast-track Diagnostics kits detect at the most four different pathogens on four different dyes, not every real-time PCR cycler is suitable. The cyclers that could be used with FTD kits are limited by the number of detection channels and the excitation- and emission wavelengths. All of the FTD kits are fully validated with the real-time PCR cyclers that are mentioned below. To correct the crosstalk for the use of LightCycler480® Fast-track Diagnostics offers a colour compensation kit that should be applied before data analysis.

Applied Biosystems® 7500 / 7500 Fast (life technologies™)

Rotor-Gene 3000 / 6000 / Q (Qiagen)

CFX96® / DX® with CFX software (BIO-RAD)

LightCycler® 480 (Roche)

SmartCycler® with Life Science software 2.0d (Cepheid)

MAIN CUSTOMERS/COLLABORATIONSMore than 200 public and private molecular biology laboratories worldwide, and the GABRIEL network, for projects funded by the Wellcome Trust and the Bill and Melinda Gates Foundation-funded PERCH project.

Fast Track Diagnostics

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Philippe Sollie

CREATION DATE 2011

EMPLOYEES 0-9



ADDRESS6d, route de Trèves L-2633 Senningerberg

CONTACT Philippe Sollie Tel: +352 26 34 06 27 [email protected]

WEBSITE www.flenpharma.com

CORE BUSINESSFlen Pharma is an international group, which was established in November 2000 in Belgium, building on the results of wound-treatment research performed by its managing director Philippe Sollie, a pharmacist, during the 1990s. Flen Pharma is a privately owned company.

Its products for wound healing are based on the moist-wound healing principle and originate from patented polymer applications and patented enzyme complexes.

PRODUCTS & SERVICESFlen Pharma’s products - Flaminal® Hydro, Flaminal® Forte, Flamigel®, Extracalm® and Flamirins®- are registered within the EU as well as in China, Switzerland and Saudi Arabia.

Its first line of products is in wound care. New products are in development in dermatological and related fields.

Flen Pharma S.A.

PR IVATE SECTOR

PUBL IC RESEARCH


CO-OWNER AND ADMINISTRATOR Jean-Paul Scheuren

CREATION DATE 2012

EMPLOYEES 0-9


ADDRESS16, rue de la Libération L-7347 Steinsel

CONTACT Jean-Paul Scheuren Tel: +352 621 15 30 83 [email protected]

WEBSITE www.houseofbiohealth.lu

CORE BUSINESSThe House of Biohealth is a unique facility where research meets business in an atmosphere that favors communication and exchange. The overall infrastructure, including the meetings areas, the conference facilities as well as the restaurant are designed to ensure that you can concentrate on your core activity.

The House of Biohealth is more than a building; it is a real opportunity to develop your activity in a dynamic scientific, economic and cultural environment.

PRODUCTS & SERVICESResearch and laboratory facility for biotechnology, ICT and greentech

Renting conditions defined in tailor-made solutions

TECHNICAL MEANS / EQUIPMENT9,500 sqm of laboratory space (modules of 150 sqm) to rent

7,800 sqm of office space, conference and communication

House of BiohealthInnovation Cluster sàrl

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Prof. Dr med Bernard Weber

CREATION DATE 1996

EMPLOYEES 100-249


ADDRESS38, rue Hiehl - Z.A.C. Laangwiss L-6131 Junglinster

CONTACT Dr Martin Schöndorf Tel: +352 78 02 90 1 [email protected]

WEBSITEwww.labo.lu

CORE BUSINESSLaboratoires Réunis (LR) is the largest independent private laboratory for medical analyses in the Grand-Duchy of Luxembourg. The headquarters are located in Junglinster where all the analyses are carried out to international quality standards. It was the first laboratory for medical analysis in Luxembourg to be ISO 15189 accredited and it has been distinguished with the national Quality Award labelled “Sur la Voie de l’Excellence”.

The activities of LR cover almost the entire domain of clinical biology and microbiology. A part of its activities are focused on applied research, especially in the domains of genetics, microbiology and infectious diseases. LR also carries out special analyses in the field of preventive medicine and of chronic functional diseases. We get samples from all over the world.

PRODUCTS & SERVICESLaboratoires Réunis has developed a nationwide network of 50 blood withdrawal centres. Blood withdrawal services are also offered at home and in companies.

Molecular Diagnostics of Infectious Diseases - LR provides a large catalogue of analyses based on multiplexed Real-Time-PCR and development of new diagnostic assays in cooperation with Fast-track Diagnostics (FTD) Luxembourg.

Preventive Genetic Tests - to improve health in terms of nutrition, lifestyle and treatment.

Environmental Medicine:

• Detection and identification of fungi and mould (which have an environmental impact) in the surroundings of the patient (in collaboration with the Association Luxembourgeoise de Médecine de l’Environnement (ALMEN) and the Luxembourg Ministry of Health)

• Genetic profiling of the individual detoxification capacities

• Stool flora scan (SFS); comprehensive assessment of the gut ecology and immunity

• ImuPro; identification of type III food intolerances

• MELISA; identification of heavy metal allergies

• Assessment of oxidative stress and antioxidative capacities of the human body.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSInternational cooperation in preventive medicine with healthcare practitioners, laboratory testing services, distributors and medical spas. Collaboration for clinical studies with international in-vitro-diagnostic companies.

Laboratoires Réunis actively contributes to applied research on clinical studies in the field of microbiology in collaboration with the universities in Frankfurt and Glasgow, as well as on genetic research in collaboration with the University of Homburg-Saar.

TECHNICAL / TECHNOLOGICAL CAPABILITIESFully automated analysis of most routine parameters

Clinical chemistry, hematology, hemostasis, immunology, microbiology, virology, etc.

Real-time PCR

Multiplexed PCR

Mass spectrometry

TECHNICAL MEANS / EQUIPMENTAnalytical chain for clinical routine analysis

MAIN CUSTOMERS/COLLABORATIONSNational & international health care providers

Laboratoire National de Santé

Laboratoire Luxemb. de Contrôle Sanitaire (LLuCS)

Ministry of Health

CRP-Santé

Deutsches Zentrum für Individualisierte Prävention und Leistungsverbesserung (DZIP)

Advanced Biological Laboratories (ABL)

Laboratoires Réunis

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Alain Huriez

CREATION DATE 2013

EMPLOYEES 0-9


ADDRESS9 avenue des Hauts-Fourneaux L-4362 Esch-sur Alzette

CONTACT Alain HuriezTel: +33 60 71 44 [email protected]

WEBSITEwww.luxfold.com

CORE BUSINESSSince the publication of the myoglobin 3D structure in 1958, a lot of research groups tried to explain the folding of protein or to predict their 3D structure. A protein’s 3D structure largely determines its functional properties. As a result, knowledge of the 3D structure of a protein can yield useful information about the functional properties of the protein. Numerous diseases are caused either by single mutations that lead to a different activity of the protein or to protein misfolding.

LuxFold has discovered a new innovative accurate method for predicting the 3D structure of proteins based solely on its coding sequence. This method gives astounding results on a wide range of protein families.

LuxFold is a spin-off from research conducted at the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg.

LuxFold S.A.

PR IVATE SECTOR

PUBL IC RESEARCH


CEO François Scalais

CREATION DATE 2009

EMPLOYEES 0-9

TURNOVER 2012 €500,000

TRADING AREA Europe


CERTIFICATIONS, QUALIFICATIONS, Authorised Private Research Centre (since September 2013)

INTERNATIONAL LOCATIONS Greater Region

ADDRESS14 rue Aldringen L-1118 Luxembourg

CONTACT François ScalaisTel: +352 26 20 34 [email protected]

WEBSITEwww.neoms.com

CORE BUSINESSAs a medical devices distributor, we provide and install surgical operating rooms equipment. As a private research centre, we develop, design and manufacture OEM Eye-Tracking solutions for the surgical market and more precisely for 3D Laparoscic surgeries.

PRODUCTS & SERVICESSurgical Operating Tables

Surgical Operating Lights

3D and 2D Laparoscopic camera and medical display

High-Defintion Medical Acquisition and/or Integrated Systems

Coming Soon: World’s First Glasses-Free 3D Surgical Display

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSOur development team develops and designs highly sophisticated, powerful and reliable tracking systems to be used in complex environments such as surgical rooms.

TECHNICAL / TECHNOLOGICAL CAPABILITIESOur tracking systems are able to detect and track even in the worst conditions: in complete darkeness, at long distance (up to 3 meters) and with two-thirds of the face hidden by a surgical mask and a surgical cap.

MAIN CUSTOMERS/COLLABORATIONSWe work in close collaboration with DFKI, German Research Center in Artificial Intelligence.

Neo Medical Systems

PR IVATE SECTOR

PUBL IC RESEARCH


CEO David Sibaud

CREATION DATE 2007

EMPLOYEES 10-49

TURNOVER 2012 €2,200,000

TRADING AREA Europe

CERTIFICATIONS, QUALIFICATIONS, ISO 9001, IS0 13 485

ADDRESS18 Op der Sang L-9779 Eselborn

CONTACT Julien BieberTel: +352 26 64 04 [email protected]

WEBSITEwww.simeda-medical.com

CORE BUSINESSSimeda is an expert in the development and manufacture of complex dental and medical prostheses in zirconium oxide (technical ceramic), titanium and Chrome Cobalt.

In the dental field, which is its core business, Simeda markets a totally digitised production system comprised of scanners that enable 3D mapping of the prostheses environment, and design software for prosthetics modelling. Digital files are sent to Simeda for the machining process.

PRODUCTS & SERVICESImplant or tooth prosthetic restorations: frames, abutments, suprastructures, overdentures

Wide choice of materials: zirconium, titanium, cobalt chromium, Peek, PMMA

Complete certified mastery of production, design and industrialisation

A truly open CADCAM solution for all laboratories

An international team of experts at the production site in Luxembourg

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSShape optimisation model for components made of brittle materials

Intra oral scanning – Optical print

TECHNICAL / TECHNOLOGICAL CAPABILITIESApart from the mechanical expertise involved in medical prostheses machining and associated equipment, Simeda specialises in reverse engineering techniques, which enable 3D mapping and digitisation of the prostheses environment for dental applications. Simeda uses and markets scanners specifically designed for these applications and offers design software developed from specifications drawn up in response to the requirements of prosthesists and dental surgeons worldwide. Both standard repair work and implant work are possible using this software.

Simeda produces and provides its own zirconia in order to master the complete chain, from the raw material to the finished parts.

TECHNICAL MEANS / EQUIPMENTSimeda is equipped with latest generation 5-axes machining centres, enabling the production of complex and precise prostheses and associated equipment in zirconium, titanium, CoCr and resin.

Simeda is using as well the laser sintering technology that allows the realization of CoCr prostheses by adding material (CoCr powder sintered by a laser beam).

Simeda also has proven expertise in reverse engineering, particularly due to mastery of photogrammetry and white-light-ray projection techniques.

MAIN CUSTOMERS/COLLABORATIONSEU dental laboratories

Implant companies

Universities

Simeda

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Roman Elsen

CREATION DATE 1998

EMPLOYEES 10-49


ADDRESS23, Am Scheerleck L-6868 Wecker

CONTACT Roman ElsenTel: +352 26 71 66 [email protected]

WEBSITEwww.te-gl.eu

CORE BUSINESST&E Gefahrgutlogistik AG is a global service provider for the logistic business specialised in handling dangerous substances and goods as well as in advice regarding the respect and implementation of national and international regulations. We support our international clients in all fields of transportation, packing, stocking and handling of dangerous substances / goods and waste products for industrial customers and the medical sector.

PRODUCTS & SERVICESWe focus on the handling of dangerous goods for all means of transportation. We develop tailored and legally compliant solutions for the packing of dangerous goods.

Our main focus is on the handling of dangerous goods in the field of hospital logistics. This includes the set-up of storage facilities for dangerous substances and authorisation procedures for laboratories and hospitals as well as the handling and transportation of infectious substances, medical samples and laboratory chemicals.

We also offer a complete and tailor-made range of training on dangerous substances and goods.

We can put an external risk prevention officer at your disposal.

We offer a 24-hour hotline for emergencies with regard to dangerous goods and related questions.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSOur specific knowledge is asked for by administrations and public research institutes as well as by our customers. Jointly with partners such as the Public Research Centre Henri Tudor we are incorporated in trend-setter projects such as “DG-Trac - Support of dangerous goods transport in the medical sector.”

TECHNICAL MEANS / EQUIPMENTWe have access to specialised transportation and packing equipment in conformity with UN regulations for all kinds of dangerous goods.

MAIN CUSTOMERS/COLLABORATIONSOur customers are widely spread from industrial customers to hospitals, laboratories and research institutes. We have set up a cooperation with Luxcontrol for trainings on hazardous substances and goods. Luxaviation is our cooperation partner for air transportation of sensitive medical samples. We are also a member of the Cluster for Logistics.

T&E Gefahrgutlogistik AG

PR IVATE SECTOR

PUBL IC RESEARCH


Managing Director Dr Stefaan Derveaux

CREATION DATE 2011

EMPLOYEES 0-9

TRADING AREA Europe

ADDRESS9, Avenue des Hauts-Fourneaux L-4362 Esch-sur-Alzette

CONTACT Stefaan Derveaux, Marizela Kuli-sic (Customer Support)Tel: +352 54 55 80 281/[email protected], [email protected]

WEBSITEwww.wafergen.com

PR IVATE SECTOR

PUBL IC RESEARCH

CORE BUSINESSWaferGen Biosystems is an emerging leader in the development, manufacture, and sale of state-of-the-art systems for genome analysis for the life science and pharmaceutical industries. Based on collaborations established with leading research institutions, WaferGen believes that the SmartChip Real-Time PCR System is positioned as the platform of choice for biomarker identification and validation.

The clinical sequencing community has been challenged with the transfer of next gen sequencing tests from research and development into the clinic. To meet this challenge WaferGen has developed the high-density SmartChip TE System for targeted sequencing. Practical benefits of this target enrichment methodology include flexibility, improved accuracy and precision with a simple, intuitive, lab-friendly workflow in target sequencing protocols. We currently have access to assay designs for the whole human exome facilitating rapid development of amplicon sequencing panels.

PRODUCTS & SERVICESWaferGen offers two instruments, the SmartChip Real-Time PCR System and the SmartChip TE System. The former combines the high-throughput nature of microarrays with the sensitivity, precision, and dynamic range of RT-qPCR. It can be used for gene expression profilling, genotyping, miRNA/lncRNA screening, and NGS validation. At its heart is a SmartChip with 72x72 nanoscale-wells (each of 100 nL), allowing the completion of 5184 qPCR reactions in 2 hours. It is available in either the SmartChip MyDesign format or as a Pre-Defined SmartChip Panel. The MyDesign format is open and flexible, allowing customers to customise the layout of their gene expression and genotyping studies according to their needs with both probe-based or SYBR chemistries. The Pre-Defined panels contain optimised assay sets already added to the chips. Current offerings include human assay panels for miRNA/lncRNA profiling, and oncology related gene expression profiling. We also offer custom panels.

WaferGen recently established a PCR-based target-enrichment workflow for next generation sequencing using SmartChips, on which one is able to enrich hundreds to thousands of target regions by amplifying each target in an individual PCR reaction thereby avoiding multiplexing interference. Following amplification, all PCR products from an individual sample are collected as amplicon pools in one centrifugation step and are ready for standard library preparation protocols.

We also can provide service on our systems.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSWe are involved in a large number of our customers’ R&D projects for which they use our technology either in their own laboratories or as a service that we provide. The local R&D project which we are going to supervise in near future is entitled ‘SmartChip qPCR arrays: towards routine clinical testing’. It will be done in collaboration with the University of Luxembourg. The aim of the project is the development of a non-coding RNA chip containing a biomarker signature specific for pancreatic cancer.

TECHNICAL / TECHNOLOGICAL CAPABILITIESHighly reproducible results are obtained within sample replicates, across multiple chips and between multiple systems. The 100nl well size ensures superior performance over other platforms. No pre-amplification is needed for most applications although one can run pre-amplified samples on the system as well. Efficient use of the chip space can be achieved to keep costs low. Flexibility with many different assay/ sample configurations and the ability to control the number of replicates per assay make it easy to use the System to fit one’s experimental design.

The development of the SmartChip TE System ensures more uniform NGS coverage. One TE panel supports conducting hundreds to thousands of parallel, singleplex PCR reactions to enrich target regions in less than 3 hours. Since amplification of each target region occurs in an individual PCR reaction, the method is not susceptible to interference due to multiplexing. This format also enables quick and easy modifications to panel content.

MAIN CUSTOMERS/COLLABORATIONSTypically, our customers are located within the larger life sciences market, including academic centres, biotech and pharmaceutical companies, agrobiotech companies, CROs, etc. Customers with limited high-throughput projects often make use of our service channel.

WaferGen Biosystems Europe S.à r.l.


Director Robert Lemor

EMPLOYEES 10-49

ADDRESS6, avenue des Hauts-Fourneaux L-4362 Esch-sur-Alzette

CONTACT Robert LemorTel: +352 42 59 91 [email protected]

WEBSITEwww.tudor.lu

PR IVATE SECTOR

PUBL IC RESEARCH

CORE BUSINESSAdvanced ICT applied to healthcare:

• Hospital and medical information systems: specialised medical or hospital applications, electronic hospital / patient record

• Mobile and wireless computing

• Medical databases

• Software development, quality and testing

eHealth:

• Patient related records and applications

• Electronic prescription

• Clinical decision support and expert systems

• Technical interoperability

• Patient identification

• etc.

ICT supported managed care:

• Telemedicine and home monitoring

• Disease management

• Managed care

Medical engineering:

• Medical devices and hospital equipment

• Ambient Assisted Living (AAL)

• Intelligent sensors

• ModelProcesses, semantical and technical interoperability in Healthcare:

• Processes in healthcare

• Processes and interconnections of the “care chain”

• Clinical pathways

• Clinical intelligence and performance

• Standardisation in healthcare

• Terminologies, classification and codification systems

• etc.

Public health:

• Health economical evaluations

• Health Technology Assessment (HTA)

• Evaluation of the impact of new methods, systems and/or solutions on quality of life and costs

• Analysis of use and efficiency of new methods, systems and/or solutions

• etc.

CRP Henri TudorResource Centre for Health Care Technologies (CR SANTEC)

Image processing:

• General image processing

• Medical imaging: RIS-PACS, imaging modalities, DICOM standard and DICOM tools, image quality, image visualisation and interpretation

• Bio-medical imaging

• Medical radiation and dose issues

Security and protection of personal data

PRODUCTS & SERVICESExamples of innovative products to improve professionals and patients everyday life:

• PAA® - A pocket device which reads the barcodes of food products and checks the list of ingredients to see whether the product contains a substance to which the user is allergic or intolerant;

• MONICARD® - Apparatus enabling the distant monitoring (telemonitoring) of patients suffering from chronic heart failure (CHF);

• GECAMed - Software for the complete management of medical practices, including appointments, administrative data, billing, medical record, prescriptions and paper as well as electronic data exchange (gecamed.santec.tudor.lu);

• OPTIMAGE - Software to automatically evaluate the quality constancy of medical images;

• WikiFood® - Portal and database providing information about the ingredients of commercially available food products, namely for allergy patients (www.wikifood.eu).

MAIN CUSTOMERS/COLLABORATIONSNational: AGFA; Associations des Médecins et Médecins Dentistes; Association Luxembourgeoise des Intolérants au Gluten; AstraZeneca; Cactus S.A.; Caisse Nationale de Santé; Direction de la Santé; Ecoinfom; eLuxembourg; Entente des Hôpitaux Luxembourgeois ; Initiative Neurodermitiskrank Kanner an Erwuessener Allergie an Asthma; Inspection Gén. de la Sécurité Sociale; Integrated BioBank of Luxembourg (IBBL); Luxembourg hospitals and medical centres; Lycée Technique d’Ettelbrück; Lycée Technique Michel Lucius; Ministry of Health; Ministry of Social Security; Pfizer; CRP-Santé; University of Luxembourg; Société Luxembourgeoise de Biologie Clinique; VoxMobile and others.

International: Deutscher Allergie und Asthmabund e.V (DE); Fachhochschule Giessen-Friedberg (DE); Fachhochschule-Köln (DE); Fachhochschule Trier (DE); Herzzentrum Bad Oeynhausen (DE); Technische Fachhochschule – Berlin (DE); Translational Genomics Research Institut – Phoenix (TGen, US); Universität zu Köln (DE); Universitaire Ziekenhuizen - Leuven (BE) and others.


CEO Dr Catherine Larue

CREATION DATE 2008

EMPLOYEES 10-49


CERTIFICATIONS, QUALIFICATIONS, IBBL is seeking ISO 9001, NF96-900 Certification and ISO17025 Accreditation

ADDRESS6, rue Nicolas Ernest Barblé, L-1210 Luxembourg

CONTACTDr Catherine LarueTel: +352 27 44 64 [email protected]

WEBSITEwww.ibbl.lu

TECHNICAL / TECHNOLOGICAL CAPABILITIES• Biospecimen research

• Kit design and production

• Sample & data storage

• DNA, RNA, protein extraction & quantification

• Cell sorting and nuclei sorting

• FFPE (formalin-fixed, paraffin-embedded) samples

• Slide preparation for histology and immunohistochemistry

• Tissue microarray construction

• Molecular biology assays

• Immunological assays

• High throughput gene expression analysis

• Phosphoprotein analysis

• Proficiency testing

TECHNICAL MEANS / EQUIPMENTInfrastructure for appropriate storage and processing of biospecimens and associated data; advanced technology platforms for genomic and proteomic analysis.

MAIN CUSTOMERS/COLLABORATIONSIBBL collaborates with partners on biospecimen collection projects, research, industrial projects, through the provision of samples to clients.

Partners include: the 5 major hospitals in Luxembourg, Laboratoire National de Santé (LNS), CRP-Santé, University of Luxembourg, Luxembourg Centre for Systems Biomedicine, International Society for Biological and Environmental Repositories (ISBER), Life Technologies, WaferGen Biosystems, Hospital of Helsingborg, Institute for Transfusion Medicine, Charité Berlin.

CORE BUSINESSIBBL is an independent, not-for-profit biobank dedicated to improving health outcomes for patients by supporting high standards of medical research.

It serves as an international centre of excellence in biobanking, and helps to accelerate the introduction of personalised healthcare in Luxembourg. IBBL collects, stores, and analyses biological samples and associated data, which are made available to research organisations investigating human diseases.

IBBL has built an integrated infrastructure offering biospecimens, data, technologies and biospecimen research to support a successful biomedical research industry in Luxembourg and facilitate rapid translation of discoveries into improved care.

The mission of IBBL is to work with the people of Luxembourg to provide high-quality specimens and data, catalyse partnerships, and support research that translates today’s discoveries into tomorrow’s healthcare solutions.

PRODUCTS & SERVICESIBBL hosts a human specimen repository that oversees the acquisition of high quality samples and data, together with a biorefinery and advanced technology platforms for genomic and proteomic analysis. This supports translational research projects, especially research to facilitate the establishment of personalised medicine. Support is provided to collaborating groups, and also on a fee-for-service basis. IBBL operates a quality management system to ensure the highest operating standards are met in our laboratories and readily shares this expertise with partners.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSUnder the umbrella of the PMC (Personalised Medicine Consortium), IBBL currently supports research programmes focused on:

Cancer: The aim is to identify and validate new molecular tools for early diagnosis of disease or help to provide patients in Luxembourg with the best personalised cancer therapy available.

Diabetes: The diabetes research team based at the University of Luxembourg runs two studies which analyse families with diabetes mellitus in an attempt to learn about the gene-environment influences known to be involved in the predisposition and onset of diabetes.

Parkinson’s Disease: IBBL works with the Luxembourg Centre for Systems Biomedicine and the Centre Hospitalier du Luxembourg to identify biomarkers associated with Parkinson’s disease, in the hope of improving options for those diagnosed.

A shared Computational Analysis Group has been created to devise the mathematical and software approaches needed to store, integrate and interpret the wealth of complex data.

IBBLINTEGRATED BIOBANK OF LUXEMBOURG

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Prof. Rudi Balling

EMPLOYEES 100-249

ADDRESSUniversity of Luxembourg Campus Belval 7, avenue des Hauts-Fourneaux L-4362 Esch-sur-Alzette

CONTACT Aurelia GiovannangeliTel: +352 46 66 44 65 [email protected]

WEBSITEwww.lcsb.lu

CORE BUSINESSThe LCSB’s main focus lies in gaining a better understanding of the molecular mechanisms underlying disease, with an emphasis on the pathogenesis of neurodegenerative diseases. New targets for prevention and intervention of neurodegenerative disease and disease pathogenesis will be analysed in the context of complex biological network composition and behaviour and interpreted as perturbations in the homeostasis of physiological networks. Mathematical descriptions of such networks will be generated and used for the modelling and simulation of how diseases develop and how they are influenced by genetic predisposition or by external environmental parameters, such as drugs, nutrition and life style.

A core area of the research is dedicated to Parkinson’s disease. Within a systems approach, genetic, molecular and cellular analysis will lead to direct clinical translation, enabled through collaboration with clinics like the CHL in Luxembourg city and CHEM in Esch/Alzette. The detailed examination of pathways involved in Parkinson related neurodegeneration, whole genome sequencing of families suffering from Parkinson disease, identification of anti-neuroinflammatory targets and the analysis of functional dynamics will offer new insights in the pathogenesis of the disease.

In our research programme, the experimental analysis of biological systems across different scales is fully integrated with the development of new technologies, i.e. in the area of high- throughput screening devices, single-cell analysis and in the field of mathematical and computational tools. The LCSB aims at a highly interdisciplinary environment at the interface of biology, medicine, mathematics and physics, combining biological experimentation with theoretical, mathematical and computational biology.

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSThe main aim of LCSB researchers is to gain a better understanding of the molecular mechanisms that underlie neurodegenerative diseases. While scientists study several neurodegenerative diseases at the LCSB, Parkinson’s disease is their main focus.

LCSB researchers who study Parkinson’s disease are striving towards three main goals:

• To be able to diagnose Parkinson’s disease at an earlier stage, before motor symptoms occur;

• To define subtypes of Parkinson’s disease based on both the patient’s symptoms and the genetic/environmental factors that cause the disease;

• To develop new treatment strategies which are more personalised and more efficient in the treatment of Parkinson’s disease.

TECHNICAL MEANS / EQUIPMENTSystems biology is driven to a large extend by high throughput and high-content technologies, such as next generation sequencing, transciptomics, proteomics, metabolomics or imaging. So far, LCSB has invested in the following specific technology platforms:

• High content cell culture screening and imaging facility

• A neuropathology platform that provides in vivo murine model development and assessment for a variety of neurodegenerative diseases

• Metabolimics and fluxomics platforms

• The LCSB bioinformatics core facility, which offers access to high performance computing and large data storage

• A zebrafish platform for gene-function analysis and in vivo screening of small molecules

• A yeast platform for functional genomics studies

MAIN CUSTOMERS/COLLABORATIONSThe LCSB is cooperating with the international leading institutions in the field of ‘Systems Biomedicine’. Our main strategic partners is the Institute for Systems Biology (ISB), Seattle (USA). Luxembourg-based partnerships include:

CRP Santé; Centre Hospitalier de Luxembourg (CHL); Integrated Biobank of Luxembourg (IBBL)

International: Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts (USA); Department of Engineering, University of Cambridge (UK); Helmholtz Center for Infection Research (HZI), Braunschweig (DE); University of Saarbrücken - HIPS, Saarbrücken (DE)

The LCSB engages in strategic partnerships with several world-leading research institutes. One objective is to ensure the best training and education for our scientists. To this end the LCSB postdoctoral fellowship programme has been initiated. In this programme, LCSB’s postdoctoral researchers spend 2 years at one of the best research institutes around the world before they return to Luxembourg to continue their scientific career at the LCSB. Current partners include the Institute for Systems Biology, Caltech, UC San Diego and the Gladstone Institute in San Francisco.

Luxembourg Centre for Systems Biomedicine (LCSB)

PR IVATE SECTOR

PUBL IC RESEARCH


CEO Prof. Iris Behrmann

EMPLOYEES 50-99

ADDRESSCampus Limpertsberg 162a, avenue de la Faïencerie L-1511 Luxembourg

CONTACT Prof. Iris BehrmannTel: +352 46 66 44 67 [email protected]

WEBSITEhttp://bio.uni.lu

CORE BUSINESSUsing fundamental molecular medicine and integrative systems biology approaches, the objective of the Life Sciences Research Unit is to gain further insights into the molecular mechanisms underlying inflammation and cancer. A particular focus is the analysis of signalling networks which are disturbed in disease situations, with the aim to identify targets for potential therapeutic intervention. Wet lab research is complemented by computational biology approaches.

Moreover, members of the Life Sciences Research Unit coordinate and contribute to the teaching of the University of Luxembourg’s study programmes Bachelor in Life Sciences, Master in Integrated Systems Biology and the Doctoral School in Systems and Molecular Medicine.

The Research Unit comprises six laboratories: Neuroinflammation, Calcium Signalling, Signal Transduction, Cytoskeleton and Cell Plasticity, Systems Biology, and Molecular Disease Mechanisms.

PRODUCTS & SERVICES• Mathematical modelling and analysis of biological / complex systems

• Screening for small molecules which target the actin cytoskeleton

• Cell-based assays for drug screening (read-outs: gene expression, proliferation, apoptosis, migration, subcellular translocation of fluorescent proteins)

• Testing of newly developed antibodies

• Concomitant intracellular calcium and superoxide release measurements by fluorometry

• Flow cytometry analyses

• Confocal microscopy imagery

• Several in vitro models of innate immune reaction

• Astrogliosis

• Differentiation of rodent neural stem cells

• Interaction between cultured cells and their substrate

• Scientific consulting

• Teaching and training in the fields of Biochemistry, Molecular Biology, and Cell Biology

• Teaching and training in the fields of Computational Biology, Bioinformatics, Mathematical Modelling

MAJOR HEALTH SCIENCES AND TECHNOLOGIES PROJECTSFNR projects, e.g.:

• Tes, a Cancer-Associated LIM-Domain Protein and Novel Actin Nucleator with a Dual Function in the Cytoplasm and the Nucleus (co-funded by FWO)

• Inflammasome Function in Neuroinflammation: a Role for Microglia in Parkinson’s Disease

• Inflammatory microRNAs in Liver Cancer (co-funded by DFG)

University of LuxembourgLife Sciences Research Unit

Fondation Cancer projects, e.g.:

• Colon cancer stem cells and hypoxia

• Spinning Disk Confocal System

IBBL project (collaboration with TGen, Phoenix, Arizona, and the ISB, Seattle):

• “Melanomics”

UL projects, e.g.:

• tandem projects with LCSB: “MetaIL6” and “ImMicroDyn1”

• Role of Notch signalling in the enteric neural stem cells

• Regulation of neutrophil functions during inflammation: Role of SNARE fusion proteins

• Focus on the early step of atherosclerosis: synergetic effect of S100A8/A9 and IL-17D

• Investigation of oncogenic signalling pathways initiated by mutated PDGFR and KIT kinases

• Molecular circuits linking L-plastin phosphorylation to breast cancer progression

TECHNICAL / TECHNOLOGICAL CAPABILITIESState-of-the-art technologies in:

• Biochemistry

• Molecular Biology

• Cell Biology

• Computational Biology

• Bioinformatics

• Mathematical Modelling

TECHNICAL MEANS / EQUIPMENTFacilities for cell culture, molecular biology and biochemistry

Hypoxia cell culture station

Quantitative epifluorescence cell imaging system (LEICA microscope, Princeton CDD camera) and data exploration software (Metaview)

FACSCanto II flow cytometer

Zeiss LSM 510 Meta confocal microscope

Spinning Disk Confocal System

Quantitative real time PCR machines (BIORAD)

Fluorimeter

Beckman ultra-centrifuge

A gel/blot detection facility, an Odyssey far-red fluorescence detection facility, a luminometer

Amaxa electroporator, spectrophotometers, Nanodrop devices

Phosphoimager

Multiwell-plate reader

Automated liquid sample distribution station

An Incucyte Kinetic Imaging System

PCs / servers with up-to-date Systems Biology and Bioinformatics software to build and analyse mathematical models of biological processes

MAIN CUSTOMERS/COLLABORATIONSNational: CRP-Santé; IBBL; Centre Hospitalier de Luxembourg; Laboratoire National de Santé; CRP Gabriel Lippmann; Axoglia; Wafergen

International: Institute for Systems Biology, Seattle (USA); TGen, Phoenix (USA); Technische Universität Dresden (DE); University of Stuttgart (DE); Universitätsklinikum des Saarlandes (DE); University of Kuopio (FI); Otto-von-Guericke-University Magdeburg (DE); University of Strasbourg (FR); University of Paris-Sud (FR); Gent University-VIB (BE); Belarus State University, Minsk (BY); DKFZ Heidelberg (DE); EMBL, Heidelberg (DE); IGBMC, Strasbourg (FR); IGMM, Montpellier (FR); University of Exeter (GB)

PR IVATE SECTOR

PUBL IC RESEARCH

Follow us on Twitter (@Luxbiohealth) and LinkedIn

c/o LUXINNOVATION GIE7, rue Alcide de Gasperi L-1615 Luxembourg-KirchbergTel: +352 43 62 63 1www.luxinnovation.lu

More informations on Luxembourg Biohealth Cluster:www.biohealthcluster.lu

The Luxembourg BioHealth Cluster is managed by With support from

LUXEMBOURG BIOHEALTH CAPABILITIES - IBBL · The Luxembourg BioHealth Cluster was established in...

Documents

Transcript of LUXEMBOURG BIOHEALTH CAPABILITIES - IBBL · The Luxembourg BioHealth Cluster was established in...